Armata CEO’s July 2026 Insider Sale Highlights Tax Strategy, Not Loss of Confidence
Armata Pharma’s CEO sells shares to cover tax, yet insider buys and FDA pediatric plan signal long‑term confidence.
3 minutes to read
ARMATA PHARMACEUTICALS INC
Armata Pharma’s Executive Option Grants Boost Confidence in Phage‑Therapy Pipeline
Armata Pharmaceuticals’ new executive option grants show strong confidence in its phage‑therapy pipeline, offering insight into leadership alignment and potential upside as the company advances toward FDA approval.
4 minutes to read